Eight analysts have recently reviewed Zimmer Biomet Holdings (NYSE:ZBH), with sentiments ranging from bullish to bearish. Over the past three months, there have been 2 somewhat bullish and 6 indifferent ratings, with no bullish or bearish ratings. The average 12-month price target is now $126.38, a 10.37% decrease from the previous $141.00 target. Analysts have adjusted their ratings and price targets in response to market dynamics and company performance, with some raising and others lowering their expectations. Zimmer Biomet designs and markets orthopedic products and has spun out its dental and spine businesses in 2022. The company's market cap is below industry averages, and it has seen a 5.02% revenue growth over three months, which is lower than its peers. Its net margin and ROE are also below industry averages, while it maintains a conservative debt-to-equity ratio of 0.45.